GlassScriptPhysician profile
Silvia Morasca
NPI 1427754985
$6,597.60
in general payments reported to CMS, 2019-2025
25 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,438 · 2024: $2,082 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,597.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,397.25 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $768.36 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $667.59 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $443.23 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $367.48 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $308.11 | 2023-2025 | Rexulti |
| Alkermes, INC. | $296.08 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $280.38 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $257.91 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $253.37 | 2023-2025 | Trintellix |
| Harmony Biosciences LLC | $213.92 | 2023-2025 | Wakix |
| Indivior INC. | $201.91 | 2023-2025 | Sublocade |
| Neos Therapeutics, LP | $152.02 | 2023-2024 | Adzenys Xr-Odt |
| Corium, LLC | $141.27 | 2023-2024 | Azstarys |
| Noven Therapeutics, LLC | $138.93 | 2024-2025 | Xelstrym, Secuado |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $128.60 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $111.67 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $107.38 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $93.35 | 2023-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $63.87 | 2023-2025 | Aplenzin |
| Pfizer INC. | $61.59 | 2025 | |
| Braeburn INC. | $49.52 | 2024-2025 | Brixadi |
| Almatica Pharma LLC | $44.89 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $31.41 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $17.51 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvia Morasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.